Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series.


Journal

Clinical neuropharmacology
ISSN: 1537-162X
Titre abrégé: Clin Neuropharmacol
Pays: United States
ID NLM: 7607910

Informations de publication

Date de publication:
Historique:
pubmed: 29 3 2020
medline: 13 4 2021
entrez: 29 3 2020
Statut: ppublish

Résumé

The treatment of Parkinson disease (PD) psychosis remains a challenge. Only a few treatments eliciting significant relief of psychotic symptoms have passed the test of randomized controlled trials. Here, we conducted a review of the literature on the effect of antidepressants on PD psychosis. Because there is no randomized controlled trial that assessed the antipsychotic effects of antidepressants in PD, only case reports, case series, and open-label trials were available to review. Because of the scarce literature, statistical analysis could not be performed. The following antidepressants alleviated hallucinations in PD: amoxapine, citalopram, clomipramine, escitalopram, mianserin, mirtazapine, and venlafaxine. The antidepressants were generally well tolerated, with the exception of amoxapine, which exacerbated parkinsonism. Whereas the conclusions that can be drawn on the efficacy of antidepressants at reducing PD psychosis are limited because of the poor quality of the reported studies, it is encouraging to notice that there are positive anecdotal reports. Further studies are needed to confirm the potential of these drugs and also to determine if a subtype of patients or of psychotic features may be more likely to be improved by antidepressants.

Identifiants

pubmed: 32217864
doi: 10.1097/WNF.0000000000000384
doi:

Substances chimiques

Antidepressive Agents 0
Citalopram 0DHU5B8D6V
Mianserin 250PJI13LM
Venlafaxine Hydrochloride 7D7RX5A8MO
Mirtazapine A051Q2099Q
Clomipramine NUV44L116D
Amoxapine R63VQ857OT

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-65

Auteurs

Lamia Sid-Otmane (L)

Département de Pharmacologie et Physiologie, Université de Montréal.

Philippe Huot (P)

Département de Pharmacologie et Physiologie, Université de Montréal.
Neurodegenerative Disease Group, Montreal Neurological Institute.
Department of Neurology and Neurosurgery, McGill University.
Movement Disorder Clinic, Division of Neurology, Department of Neurosciences, McGill University Health Centre.

Michel Panisset (M)

Département de Pharmacologie et Physiologie, Université de Montréal.
Department of Neurology and Neurosurgery, McGill University.
Unité des troubles du mouvement André-Barbeau, Service de Neurologie, Département de Médecine, Centre Hospitalier de l'Université de Montréal.
Département de Neurosciences, Université de Montréal, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH